# Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19

> **NCT04568863** · PHASE2 · COMPLETED · sponsor: **Pharmamel S.L.** · enrollment: 18 (actual)

## Conditions studied

- COVID-19
- SARS-CoV 2
- Coronavirus Infection

## Interventions

- **DRUG:** Melatonin intravenous
- **DRUG:** Placebo intravenous

## Key facts

- **NCT ID:** NCT04568863
- **Lead sponsor:** Pharmamel S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-20
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-03-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04568863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04568863, "Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04568863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*